

Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1

NCT06188741

Status	RECRUITING
Phase	Phase 2
Sponsor	University of Alabama at Birmingham
Enrollment	200 participants

Key Eligibility Criteria

Inclusion (47)

- PART 1:
- Age: ≥ 1 (≥ 12 months) and ≥ 8 years of age at the time of study enrollment.
- Diagnosis: Participants with a diagnosis of NF1 based on the 2021 revised consensus criteria [52] and
- No known PN (prior to enrollment on Part 1). Participants for whom there is clinical suspicion for a PN (e.g., subtle facial asymmetry or large overlying hyperpigmented area) may be included in the study after discussion with the Study Chair so long as they have not previously had an MRI of the region of concern and are otherwise asymptomatic.
- Physical exam at your institution within 1 year prior to consent.

... and 42 more (see full listing online)

Exclusion (60)

- Presence of a known, symptomatic PN with or without previous MRI imaging.
- Patients who have had previous whole-body MRI (WBMRI) are excluded from the study. However, patients who have had regional MRI(s) for an indication other than a PN and did not have a PN identified on previous MRI may still be eligible for the study.
- Inability to undergo MRI and/or contraindication for MRI examinations following the MRI protocol.
- Prior treatment with selumetinib or another specific MEK1/2 inhibitor.
- Evidence of an optic pathway or other low-grade glioma, high grade glioma, malignant peripheral nerve sheath tumor, or other cancer/tumor requiring treatment with chemotherapy, biologic therapy or radiation therapy.

... and 55 more (see full listing online)

Locations (13 total)

Childrens of Alabama, Birmingham, Alabama, United States
Children's Hospital of Los Angeles, Los Angeles, California, United States
Children's National Hospital, Washington D.C., District of Columbia, United States
... and 10 more locations

<https://clinicaltrials.gov/study/NCT06188741>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at ClinicalTrials.gov. Generated by ClinicalTrialsFinder.org.